failure or nephrotic syndrome, symptoms are usually present for about 3 months. Patients with neuropathy or slowly progressive hepatomegaly may be symptomatic for a year before diagnosis. Diagnosis requires biopsy, either of a surrogate site (i.e., the abdominal fat or rectum) or of an involved organ. Visualizing amyloid with both Congo red staining and EM enhances diagnostic confidence. The presence of symptomatic cardiac amyloid is a poor prognostic factor for survival. 8 A third of patients present with significant albuminuria (> 500 mg/d), often with few symptoms associated with other organs of involvement, whereas another third of patients present with symptoms of cardiac involvement, including orthopnea, dyspnea on exertion, and findings of diastolic dysfunction and left ventricular hypertrophy without hypertension. 9 Liver and gastrointestinal involvement is prominent at presentation in a quarter of patients, with complaints that can include right upper quadrant discomfort, abdominal distension, weight loss, early satiety, and gastrointestinal bleeding. Peripheral neuropathy occurs in approximately a fifth of patients at presentation and can cause sensorimotor symptoms that begin in the lower extremities and autonomic symptoms that can include orthostasis, diarrhea or constipation, and erectile dysfunction. One third of patients present with 3 or more organ systems involved. 2 Macroglossia and periorbital purpura, which are distinctive findings of AL amyloidosis, occur in one sixth of patients. Fatigue and loss of libido are commonly reported on review of systems.
The evaluation at diagnosis includes testing for organ involvement and type of amyloid (Table 1) . Concerns about whether amyloid is AL or another type are warranted because myelotoxic chemotherapies have no place in the treatment of non-AL and because failure to diagnose a hereditary disease has consequences. Family history is not a useful guide for hereditary disease and, with the exception of renal biopsies, tissue staining for amyloid typing is unreliable. Investigators at 2 centers reported patient series (N = 178 and N = 350) in which 2% to 10% of patients presumed to have AL had both a monoclonal gammopathy and a hereditary mutant protein, either transthyretin or fibrinogen A-␣. 10, 11 Because a hereditary mutant transthyretin (the valine-122-isoleucine variant) occurs in 4% of African-Americans, who also have a higher incidence of monoclonal gammopathy, those who present with amyloid must be tested for both sources. The authors also recommend testing patients presenting with peripheral neuropathy for a hereditary source of disease. Patients with 2 possible sources should 
Liver and Gastrointestinal Tract
Alkaline phosphatase, liver enzymes, bilirubin
Stool guaiacs
Gastric emptying scan (if gastroparesis present)
Ultrasound or computed tomography scan to document craniocaudal liver span be referred to centers specializing in amyloidosis for typing and treatment. The practitioner who rarely sees patients with amyloidosis must also be sensitive to the occurrence of localized light-chain and systemic senile amyloidosis. The larynx, tracheobronchial tree, lungs, duodenum, and bladder are the most common sites of localized AL amyloidosis; it rarely progresses to systemic disease. 12 Approximately one quarter of patients will have abnormal FLC. Senile systemic amyloidosis usually presents with cardiac involvement in men older than 70 years, although the lungs can sometimes be symptomatically involved and progression can be rapid in rare cases. 13 Patients who may have localized or senile systemic amyloid should also be referred to centers specializing in amyloidosis for diagnostic confirmation.
A role for BNP and troponin testing has been established in AL. Because cardiac involvement is prevalent, these biomarkers are useful in screening. 14 A staging system using both N-terminal (NT)-proBNP and troponin C has been developed. 15 Patients with pronounced elevations of both BNP and troponin have a poor prognosis. 16 These biomarkers may also be useful in managing patients. The BNP can decrease in cardiac patients when the precursor FLC is reduced with therapy; however, these tests are nonspecific and can vary because of factors other than progression or hiatus of cardiac amyloid. 17 Ig light chains are produced in slight excess by normal plasma cells and occasionally in significant excess by clonal plasma cells. Ig light chains circulate in normal individuals and can be measured using the serum FLC assay. 18 The FLC assay is quantitative, unlike immunofixation, and is more sensitive to the presence of clonal disease than immunofixation in many cases. FLC levels and ratios are abnormal in more than 95% of patients with AL, and the elevated FLC is usually the precursor protein. The FLC assay has significantly changed the way patients with AL are diagnosed and monitored during therapy. 19, 20 Decreases in the pathologic FLC of 50% or more with treatment are associated with significantly better survival; the goal of therapy, however, should remain normalization of the pathologic FLC and kappa:lambda ratio. 21 Most patients have a marrow plasma cell fraction of less than 10% and lack the classic M-spike of myeloma on protein electrophoresis. 22 Immunofixation studies are more helpful than electrophoretic ones for diagnosing the monoclonal gammopathy in AL. Lambda clones dominate kappa ones by a 4:1 ratio, unlike the 2:3 ratio in myeloma. Baseline evaluation of the plasma cell dyscrasia includes the FLC assay, serum and urine immunofixation and protein electrophoresis, and immunohistochemical staining of a marrow biopsy for CD138, kappa, and lambda, and for amyloid with Congo red. AL on rare occasions can be associated with light-chain secreting lymphoplasmacytic disorders, so testing would then include radiographic and tissue studies appropriate for lymphoma. In these cases, patients often have nodal amyloid that, unlike lymphoma, and no matter how massive, is usually negative with positron-emission tomography. 23 The plasma cell dyscrasia in most patients with AL amyloidosis is the equivalent of a monoclonal gammopathy of undetermined significance. The repertoire of Ig light-chain variable-region germline genes in AL is skewed, and the basis for this is unknown. 24 Severe anemia, lytic bone lesions, hypercalcemia, and hyperviscosity are not features of AL. Coagulation abnormalities may occur in patients with hepatosplenic AL because of deficiencies of factor X and dysfibrinogenemias, and visceral rupture also occurs in a small fraction of patients.
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Treatment
The only effective therapeutic approach is to reduce the production of amyloid-forming FLC. The FLC assay provides a direct quantitative measure of response. The conundrum of therapy is that treatments that may work gradually are likely to be ineffective because organ disease continues to progress. Criteria for assessing hematologic and organ responses have been defined and are in widespread use. 9 Therapies for AL based on clinical trial results are shown in Table 2 . Cases illustrating FLC responses and tracking of BNP levels are shown in Figure 1 .
Serum FLCs and BNP are among the most useful measurements in diagnosing and treating patients with systemic AL amyloidosis. The FLC measures Ig light chains unassociated with heavy chains and is usually the best measure of the toxic precursor-protein; the FLC has a half-life of hours. The FLC is the target for therapy with the goal of reducing the FLC and the kappa:lambda ratio to normal. The BNP is a surrogate marker for amyloid cardiac involvement. BNP is not specific for cardiac involvement and can be affected by intercurrent clinical cardiopulmonary events; hence, the value in using the FLC and BNP together to avoid the logical trap of attributing all clinical occurrences to amyloid in patients with AL. Organ responses and clinical improvements lag behind the response of the FLC. Relapse of organ involvement occurs out-of-phase with the FLC also. These 3 cases of biopsy-proven AL amyloidosis cardiac involvement are illustrative (Figure 1) .
Oral melphalan and prednisone was the first therapy shown to be beneficial in phase III trials. 27, 28 Overall median survival was prolonged from 8 to 18 months and hematologic response rate was 20% with a median time to response of 12 months. Patients who survived more than 3.5 years after receiving oral melphalan had a 20% of risk for myelodysplasia, often leading to secondary leukemia. 29 A multicenter phase II trial testing pulse dexamethasone, followed by maintenance therapy with dexamethasone and alphainterferon, led to hematologic responses in 53% of evaluable patients with 24% experiencing complete responses. 30 Organ response rate was 45%. Median survival of the entire cohort was 31 months, with estimated 2-year overall and event-free survivals of 60% and 52%, respectively. In a phase II trial using oral melphalan and dexamethasone in patients not eligible for SCT, the response rate was 67%, with 33% complete responses. 31 Median time to response was 4.5 months. Organ response rate was 48%. Two treatment-related deaths occurred in the first 100 days of therapy and 1 patient subsequently developed myelodysplasia. Median survival exceeded 4 years (Giampaolo Merlini, MD; personal communication). In a phase II trial of thalidomide and dexamethasone combined as salvage therapy, with thalidomide dosed at 100 mg/d with increments up to 400 mg and dexamethasone at 20 mg/d on days 1 to 4 every 3 weeks, the hematologic response rate was 48% with 19% complete responses. The response rate was higher in those taking higher doses of thalidomide 32 and the median time to response was 3.6 months. Organ response rate was 26%. Fluid retention and symptomatic bradycardia without QT prolongation were common adverse reactions, whereas neuropathic and thromboembolic complications were rare.
Oral melphalan and dexamethasone is the most active oral regimen based on phase II data and is currently considered standard therapy for patients who have not undergone SCT. In frail or elderly patients, a 50% dose-reduction is often effective and tolerable. The oral combination is easily administered, is usually given for 6 to 12 months depending on the response of the FLC, and can be considered equivalent tomelphalan-based SCT except for the risk for myelodysplasia and secondary leukemia. In patients experiencing failed response to melphalan and dexamethasone, thalidomide and dexamethasone should be considered first-line salvage therapy, although both bortezomib and lenalidomide are in clinical trials and likely will have significant activity.
The efficacy of SCT in reversing the clinical manifestations of AL in most surviving patients has been documented at numerous centers. 33, 34 In the largest series of patients reported (N = 312, from a single center), the median overall survival post-SCT was 4.6 years with 47% surviving at 5 years. 35 For patients without cardiac involvement at SCT, the median survival was 6.4 years with a 60% 5-year survival rate, whereas the median survival for those with cardiac involvement at SCT was 1.6 years with a 29% 5-year survival rate. At 1-year post-SCT, 44% of evaluable patients experienced organ responses. The complete response rate was 40% and was associated with an 82% 5-year survival rate compared with 55% for those not experiencing complete response. Many patients, however, had been diagnosed more than 12 months before undergoing SCT and treated previously with oral agents.
A more relevant picture is obtained in a randomized, prospective phase II clinical trial of SCT in patients enrolled within a year of diagnosis and not previously treated. 36 Patients (N = 100) were stratified based on organ involvement and time from diagnosis and were then randomized 1:1 to undergo initial SCT or SCT after 2 cycles of oral melphalan and prednisone. The 100-day treatment-related mortality rate was 20%, and 12% of patients died from causes associated with stem cell mobilization. No significant differences occurred between the 2 arms with respect to overall survival at a median of 4 years follow-up. At 5 years post-SCT, the overall survival rate was 50% for immediate and 39% for delayed SCT. The complete response rates in patients evaluable at 12 months were 32% and 30%, and 42% of patients experienced an organ response at 1 year. Fewer patients randomized to initial oral therapy underwent SCT because of disease progression that made them ineligible for SCT, which affected patients with cardiac involvement disproportionately. Newly diagnosed untreated patients with AL eligible for
Original Article 183
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Overall survival was a function of the number of organ systems clinically affected and the presence of cardiac involvement, confirming earlier observations. 37, 38 For patients with 1 or 2 major organ systems affected, including heart, kidneys, liver/gastrointestinal tract, and peripheral nervous system, and for those without symptomatic cardiac involvement, median survival was not reached at a median of 4 years followup. For the others, median survivals in the 2 groups were 9.3 and 5.2 months for patients with 3 or more organs involved, and 9.6 and 4.8 months for cardiac patients. SCT can be safely applied to patients with AL amyloidosis who do not have symptomatic 3-or 4-organ system involvement or advanced cardiac amyloid characterized by recurrent pleural effusions, cardiac syncope, or symptomatic arrhythmias.
French investigators conducted a randomized prospective multicenter phase III trial (N = 100) in which SCT with standard intravenous melphalan was compared 1-to-1 with oral melphalan and dexamethasone given continuously for up to 18 months. 39 The SCT group showed a 44% early failure rate caused largely by treatment-related deaths and disease progression. (In comparison, a multicenter national studygroup phase II trial in the United States had a 10% treatment-related mortality. 31 ) Analysis of outcomes between the groups showed that patients treated at most centers (27 of 29) had far better survival if they underwent oral therapy (P < .01), whereas patients in the 2 centers at which the largest fraction of SCTs were performed had better survival rates with SCT. Comparisons of response and survival rates between those alive at least 3 months post-SCT and those who completed at least 3 months of treatment with oral melphalan and dexamethasone showed no difference. The hematologic response rate for both groups was 65%. The organ response rate was higher in the SCT group (52% vs. 40%). Median survival was 48 months for SCT and 58 months for oral therapy. Surprisingly, no cases of myelodysplasia were reported in the oral melphalan group.
This phase III trial did not clearly define a standard therapy for AL. A case-cohort analysis showed a survival advantage in patients treated with SCT who had good performance status. 40 Quality of life improves significantly in patients who experience response to SCT. 41 The difference between 12 or 18 months of treatment with oral melphalan and dexamethasone and SCT is that, as in myeloma, SCT is not simply a solitary modality, but rather one that provides a platform for therapy with a low risk for myelodysplasia. SCT is currently a useful initial therapy to which adjuvant treatments can be added to improve response rates. The caveat is that, given the activity of standard oral regimens to which thalidomide has been added to treat myeloma, further study of melphalan and dexamethasone combined with new agents is clearly also warranted. 42, 43 The authors recently completed a phase II trial prospectively testing a combined approach of riskadapted melphalan and SCT with adjuvant thalidomide and dexamethasone post-SCT. 44 In risk-adapted melphalan dosing, the dose of intravenous melphalan is attenuated based on age and organ involvement; this schema is based on the dose-related differences in toxicity observed in clinical trials at different doses of melphalan for AL and on age-related differences in survival in patients with AL. 34, 45, 46 Riskadapted dosing is a strategy for reducing treatmentrelated mortality. Eligible patients for this trial had to be untreated and diagnosed within 12 months of enrollment. Patients underwent autologous SCT with melphalan dosed at 100 to 200 mg/m 2 based on age, renal function, and cardiac involvement. Those not achieving a hematologic complete response at 3 months post-SCT underwent 9 months of treatment with dexamethasone (20 mg/m 2 , 1-3 pulses monthly) and thalidomide (50-200 mg nightly), or with only dexamethasone if they experienced prior deep venous thrombosis or neuropathy. Aspirin was used for thromboembolic prophylaxis.
In this study, treatment-related mortality was 4.4% (2 of 45 patients). At 3 months post-SCT, 61% of patients had hematologic responses. Persistent clonal plasma cell disease was found in 34 patients; 1 patient refused and 2 were too ill to undergo adjuvant therapy. Twenty-two patients received thalidomide and dexamethasone, and 9 received dexamethasone alone. With adjuvant therapy, almost half of patients experienced improved responses at 12 months, including 6 who experienced complete responses. No treatment-related deaths occurred in the adjuvant phase and toxicities were manageable. The response rate at 12 months was 77%, with 38% complete responses; no difference occurred in response rate based on the dose of melphalan. At 12 months, 52% expe-rienced organ responses, whereas 29% experienced stable and 19% worsened organ function. With a median follow-up of 20 months, overall survival is 76% and median survival is not yet reached. Further study of these combined approaches is warranted using SCT as a platform for therapy in AL.
Although criteria for organ responses have been defined and widely implemented, several points about variability in organ recovery bear mentioning. With a complete hematologic response, the liver can remove amyloid, regenerate, and return to normal size and function. Peripheral and autonomic nervous system involvement can be reversed, perhaps because a component of dysfunction is caused by the toxic effects of FLC. Proteinuria can decline dramatically in hematologic responders, but creatinine clearance rarely improves and the kidneys remain at risk from nonamyloid insults. Cardiac involvement also remains problematic; the details of long-term follow-up of patients with cardiac amyloid are poorly recounted. Only 20% of cardiac patients with hematologic responses show objective improvement on echocardiogram. With serial studies showing BNP decline in conjunction with FLC response, experts now know that less injury or strain may occur as the precursor protein is eliminated. Over time, however, and despite complete hematologic responses, patients with cardiac amyloid can experience declining cardiac function and sudden arrhythmic events. An effective approach to monitoring and treating these patients, even with interventions such as low-dose antiarrhythmic agents or anticoagulation, remains to be prospectively defined.
Solid Organ Transplantation and New Approaches
Young minimally symptomatic patients in the United States and Europe with hereditary amyloidosis caused by variant transthyretin are usually considered candidates for curative solid organ (e.g., liver) transplantation, partially because of the potential for "domino" transplants. 47, 48 That is, the amyloid patient's variant-transthyretin-producing liver is used for another recipient. Ironically, at the same time, the use of solid organ transplantation (liver, heart, and kidney) in patients with AL is usually deemed poor risk because of the likely accumulation of amyloid in the grafted organ. However, numerous patients have successfully undergone cardiac allograft and then SCT, and the feasibility of this approach is established. 49 Renal transplantation has also been shown to be effective and renal allografts survive for lengthy periods in many recipients. 50 New agents in clinical trials include lenalidomide, bortezomib, and monoclonal antibodies. The development of amyloid-reactive monoclonal antibodies was based on the premise that an immune reaction to amyloid deposits might help stimulate fibril disassembly. 51 The 11FA monoclonal, linked to 124 iodine, is currently being studied as an imaging agent.
Conclusions
Tests and treatments for AL are improving. Although the disease is rare, the availability of easily measured, biologically relevant laboratory values and an increasing number of active regimens will likely improve outcomes. The FLC and BNP assays have improved diagnostic testing and the ability to monitor response to therapy. Developing a widely available nuclear imaging scan for assessing organ involvement is a goal for the near future. At centers with experience, SCT for AL remains effective in patients with limited disease; it can be risk-adapted to optimize benefit and limit mortality and provides a platform for testing novel post-SCT adjuvant therapies. Outcomes with oral therapy are also likely to improve as new agents such as thalidomide, lenalidomide, and bortezomib are tested in combination with melphalan and dexamethasone. Solid-organ transplantation can play an important role in treating selected patients and merits further study.
As insight is gained into the basis of light-chain cellular toxicity, cytoprotective pathways may provide opportunities for drug discovery, helping to rescue organs from the damage of amyloid. As experts gain a better understanding of the AL amyloidosis plasma cell, targets on the cell surface and in survival pathways may be identified, aiding the development of new approaches, and investigators will continue to seek agents that inhibit fibril formation and mobilize fibrils from organ deposits. Advances have been made in clinical trials with translational objectives and, whenever possible, patients with systemic light-chain amyloidosis should be enrolled and treated on such studies.
